3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
22
Leukemia
15
Lymphoma
11
Leukemia, Erythroblastic, Acute
8
Prostatic Neoplasms
7
Leukemia, Myelomonocytic, Acute
7
Leukemia, Monocytic, Acute
7
Leukemia, Megakaryoblastic, Acute
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Follicular
6
Myelodysplastic Syndromes
5
Lymphoma, Non-Hodgkin
5
Lymphoma, Large-Cell, Immunoblastic
5
Anemia, Refractory, with Excess of Blasts
4
Leukemia, Promyelocytic, Acute
3
Congenital Abnormalities
3
Breast Neoplasms
3
Pain
2
Neutropenia
2
Myeloproliferative Disorders
2
Leukemia, Myelomonocytic, Chronic
2
Burkitt Lymphoma
2
Sarcoma, Myeloid
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Myelodysplastic-Myeloproliferative Diseases
1
Lymphoma, Large-Cell, Anaplastic
1
Interventions
osimertinib
1
obinutuzumab
1
midostaurin
1
flumatinib
1
fludarabine
1
Radiotherapy
1
Oxaliplatin
1
Mitoxantrone
1
Mercaptopurine
1
Leucovorin
1
Irinotecan
1
Gemtuzumab
1
Folfox protocol
1
Fluorouracil
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm, Residual
×
Mitoxantrone
×
Clear all
NCT02724163
2021-10-08
Myechild01
University of Birmingham
Phase 3
Recruiting
700 enrolled